Summary
Updated Aug 30, 2026
Peggy Scherle is Chief Scientific Officer of Prelude Therapeutics Inc (PRLD). 1 SEC Form 4 filing on record, dated 5 February 2026.
Trading Pattern
InsiderAlpha's records for Peggy Scherle go back to 2026: 1 primary Form 4 filing, an average of 1.0 per year. No transaction on record carries a Rule 10b5-1 flag - the filings look discretionary rather than pre-scheduled, which makes their timing more informative as a signal.
Other Insiders Active in the Same Stocks
Insiders who reported open-market trades in the last 12 months at the companies Peggy Scherle files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- ORBIMED ADVISORS LLC - $12.50M of PRLD open-market activity in the last 12 months
- David P. Bonita - $12.50M of PRLD open-market activity in the last 12 months
- BAKER BROS. ADVISORS LP - $10.00M of PRLD open-market activity in the last 12 months
More Notable Insiders
Other corporate insiders with significant SEC Form 4 track records on InsiderAlpha:
Frequently Asked Questions
Who is Peggy Scherle?
Peggy Scherle is a corporate insider, tracked as Chief Scientific Officer of Prelude Therapeutics Inc (PRLD). InsiderAlpha holds 1 primary Form 4 filing for them, the earliest from 2026, updated as new SEC EDGAR filings are processed.
When did Peggy Scherle last file a Form 4?
The only primary Form 4 on record is dated 5 February 2026.
Where can I see all of Peggy Scherle's SEC filings?
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Learn More
Follow Peggy Scherle and every insider like them
A free account opens the full scored daily plan and every past day, a watchlist for any ticker, and 3 months of price history on every company page. No card.
Free plan available · Paid plans start with a 7-day free trial